 |
$1-5bn seen optimal for biotech M&ABiotech deals in the $1 billion to $5 billion range are likely to be a sweet spot for drug companies looking to bolster their pipelines through M&A in an increasingly tough environment, Ernst & Young said. Big pharma companies are More… |
Thursday 26 December 2024
